Table 3 Serum levels of nCD64, CRP and procalcitonin in studied groups
|  | Group1 (cancer with FN) (n = 50) | Group 2 (cancer without FN) (n = 25) | Group 3 (healthy controls) ( n = 25) | Test | P |
|---|---|---|---|---|---|
nCD64 (%) | |||||
 Min.– Max. | 16.03–63.12 | 6.82–36.67 | 7.08–29.15 | H = 53.15 | < 0.001 |
 Median (IQR) | 28.71(25.38–34.81) | 16.65 (10.89–25.12) | 12.57 (9.25–14.71) | ||
 Posthoc test | P1 < 0.001 | P2 = 0.115 | P3 < 0.001 | ||
C-Reactive protein (CRP) | |||||
 Min.– Max. | 3.0–280.0 | 3.0–9.0 | 2.9–9.0 | H = 64 | < 0.001 |
 Median (IQR) | 56.45(15.45–129.63) | 5.6 (3.05–6.0) | 3.0(3.0–3.75) | ||
 Pairwise test | P1 < 0.001 | P2 = 0.299 | P3 < 0.001** | ||
Procalcitonin(ng/ml) | |||||
 Negative (< 0.5)  Positive (> 0.5) | 33 (66.0%) 17 (34.0%) | 20 (80.0%) 5 (20.0%) | 25 (100.0%) 0 (0.0%) | χ2 = 11.3 | 0.004 |
 Min.– Max.  Median (IQR) | 0.02–14.77 0.44 (0.11–7.03) | 0.02–0.81 0.09 (0.04–0.34) | 0.03–0.39 0.06(0.04–0.1) | H = 20.43 | < 0.001 |
 Pairwise | P1 = 0.005 | P2 = 0.212 | P3 < 0.001 | ||